IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP reduced its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 86.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,252 shares of the company's stock after selling 343,236 shares during the quarter. ExodusPoint Capital Management LP owned 0.06% of IDEAYA Biosciences worth $1,343,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Norges Bank purchased a new stake in IDEAYA Biosciences during the 4th quarter worth $13,385,000. State Street Corp grew its stake in shares of IDEAYA Biosciences by 15.4% in the third quarter. State Street Corp now owns 3,317,936 shares of the company's stock valued at $105,112,000 after buying an additional 443,640 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after buying an additional 282,936 shares during the period. WCM Investment Management LLC acquired a new position in IDEAYA Biosciences during the 4th quarter worth approximately $6,030,000. Finally, JPMorgan Chase & Co. boosted its holdings in IDEAYA Biosciences by 244.3% in the 4th quarter. JPMorgan Chase & Co. now owns 274,693 shares of the company's stock worth $7,060,000 after acquiring an additional 194,913 shares during the period. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA traded down $0.30 during trading on Tuesday, reaching $16.82. The stock had a trading volume of 400,582 shares, compared to its average volume of 927,588. The firm's 50 day moving average price is $18.70 and its two-hundred day moving average price is $24.16. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $44.42. The stock has a market cap of $1.47 billion, a PE ratio of -5.08 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. On average, research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on IDYA. Stephens reiterated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Wedbush restated an "outperform" rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IDEAYA Biosciences currently has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.